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Peutz-Jeghers syndrome is a rare autosomal dominant inherited disease characterized by a special type of hamartomatous
gastrointestinal polyps combined with mucocutaneous melanin pigmentations. Patients with t h es y n d r o m eh a v eah i g hr i s ko f
developing neoplasia, with colon, small bowel, and stomach being the most common gastrointestinal sites. Herein, we present
the occurrence of a rare tumor in patients with Peutz-Jeghers syndrome; a cholangiocarcinoma of the endopancreatic bile duct. A
minireviewisalsopresented. It canbe concludedthatcholangiocarcinomaremainsapossiblediagnosisinPJSpatients,asinothers
that present with biliary obstruction. PJS patients may be at higher risk than others in view of their propensity for malignancy.
1.CasePresentation
A 31-year-old Caucasian male patient of Greek origin
presentedwitha progressivelyincreasing painless obstructive
jaundice. The patient was known to have Peutz-Jeghers
syndrome (PJS) since childhood. He was genetically tested
for the syndrome (germline mutation in STK11), which
was conﬁrmed in Norwich, England where the patient was
born and lived for 25 years. There was no family history
of PJS or gastrointestinal carcinoma. Four months ago, the
patient underwent surgery for intestinal obstruction and
intussusception where a part of small bowel was excised.
Biopsyrevealed hamartomatous polypsconﬁrming histolog-
ical proof of PJS. The patient made a good recovery but
4 months later developed painless obstructive jaundice and
was referred to our surgical department for further investi-
gation and treatment.
Clinical examination conﬁrmed the jaundice, and there
were clear manifestations of PJS, with pigmented lesions
around the mouth and on the hands. The patient reported
weight loss in the last couple ofmonths with no other appar-
ent clinical abnormalities. A well-healed midline abdom-
inal surgical scar was found. Biochemical investigations
conﬁrmedtheobstructivenatureofthejaundicewithadirect
bilirubinof5.56mg/dL,alkalinephosphataseof231U/L,and
aspartate aminotransferase of 163U/L. Haemoglobin was
10.4gr/dL, and the prothrombin time was prolonged at 15.2
seconds. Tumor markers were negative. X-rays of the chest
and abdomen were unremarkable.
Ultrasound showed dilated biliary tree and gallbladder.
MRCP conﬁrmed the previous ﬁndings and revealed an
obstruction at the lower end of the common bile duct
(Figure 1). This was conﬁrmed by CT scan which also
revealed multiple polyps of the stomach, duodenum, and
intestine (Figure 2). ERCP was unsuccessful owing to dif-
ﬁculty revealing Vater’s ampulla due to space-occupying
duodenal polyps.
Adecisionforthepatienttoundergosurgicallaparotomy
was taken. The duodenum was found distended and full
of polyps. The gallbladder and the common bile duct were
grossly dilated. The liver carried diﬀuse rice-like metastases
throughout (Figure 3); enlarged hepatoduodenal lymph
nodes were also identiﬁed. Frozen section biopsy of the liver
and lymph nodes revealed metastasis from adenocarcinoma
of unknown origin. The duodenum was dissected, and the
polyps were excised (Figure 4). Due to the progression of the2 HPB Surgery
Figure 1: Magnetic resonance cholangiopancreatography showing
dilated biliary tree and gallbladder. Arrow points at obstruction at
the lower end of the common bile duct.
Figure 2: Contrast-enhanced axial computer tomography scan
showingmultiple polyps of the stomach, duodenum, and ileum.
disease, cholecystectomy and end-to-side choledochojejunal
anastomosis were performed. A 1cm ring from the distal cut
end of the bile duct was also sent for pathology examination.
The pathology report revealed a poorly diﬀerentiated
cholangiocarcinoma of the common bile duct with liver
metastases and positive hepatoduodenal ligament lymph
nodes (station 12b). The carcinoma presented partially
neuroendocrine diﬀerentiation. The immunophenotype of
the neoplasm was the following: AE1/AE3:+++, CK7:+++,
CAM5.2:+++, polyclonic CEA:++, CK34Be12:+, CK18:+,
synaptophysin:+++, NSE:+, polyclonic Ca 19-9:−, Ki67:+ in
30% of cancer cells, P53:+ in 80% of cancer cells, Cerb2:
expressed in <10%, EGFR:+ in 30%, and Ckit:−.
Postoperatively, the patient made an uneventful recovery
and was discharged home two weeks later. A month postop-
eratively, he started medical treatment with chemotherapy.
He received 3 cycles of oxaliplatin, capecitabine, and beva-
cizumab. Decision not to include another chemotherapeutic
agent like mTOR inhibitors (e.g., everolimus) to the regimen
wasmadebythesurgicalandmedicaloncologyteamsdespite
the partially neuroendocrine nature of the neoplasm. The
Figure 3: Intraoperative ﬁnding of diﬀuse rice-like metastases
throughout the liver (arrows).
Figure 4: Excised large Peutz-Jeghers polyps from the duodenal
wall.
patient showed no response to treatment and deceased 4
months later of generalized carcinomatosis.
2.Discussion
Peutz-Jeghers Syndrome (PJS) is a rare autosomal dominant
inherited disease characterized by a special type of hamar-
tomatous gastrointestinal polyps (PJ polyps) combined with
mucocutaneous melanin pigmentations [1, 2]. PJ polyps
are characterized by extensive smooth muscle arborization
throughout the polyp and occur throughout the alimen-
tary tract—sparing the esophagus—with a predilection for
the small bowel with decreasing frequency from jejunum,
ileum, colon, rectum, stomach, to duodenum. Extraintesti-
nal polyps are rare but may occur in the ureter, nasal cavity,
or gallbladder. Pigmented lesions are detectable in 95%
of patients with PJS and are potentially disappearing with
age. They vary in size, number, and color [3]. Predilection
sites are the lips, the peri- and intraoral regions and less
c o m m o n l yt h er e c t u m ,f e e t ,v u l v a ,a n dc o n j u n c t i v a .T h e
diagnosis of PJS is based on criteria including at least two PJHPB Surgery 3
polyps, one PJ polyp and mucocutaneouspigmented lesions,
or one PJ polyp and positive family history of PJS [4].
Negative family history (up to 45% of index cases)
indicates a high incidence of de novo germline mutations.
Symptoms, typically occuring in adolescence or young
adulthood, include recurrent colicky abdominal pain due
to intussusception of small bowel segments caused by
large polyps and can be complicated by acute intestinal
obstruction and paralytic ileus of a small bowel segment.
Occult gastrointestinal bleeding and iron deﬁciency anemia
may be other presentations of the syndrome. Impressively,
pigmentation may be present in early childhood and may
fade away or even disappear over the lifetime [3, 4].
Areas with intraepithelial neoplasia and cancer may
occur in PJ polyps. Up to date, whether intraepithelial
neoplasia predisposes to cancer following a “hamartoma-
adenoma-carcinoma sequence” is still debatable. There
are studies suggesting that a “hamartoma-adenocarcinoma
sequence” can be applicable [5, 6]. On the other hand, and
what is believed to be the case today for the majority of PJ
polyps, is what has been shown from more recent studies.
Based on the rarity of the atypia/dysplasia found on the PJ
polyps, these studies argue against a “hamartoma-adenoma-
carcinoma sequence” [7]. The clinical course is usually
characterized by multiple surgical procedures for benign
small bowel complications (intussusception, bleeding, and
obstruction) [4].
The causative locus for PJS was elucidated by targeted
linkage analysis and comparative genomic hybridization to
be on chromosome 19p13-3 [8]. The gene that has been
identiﬁed as LKB1 (also known as STK11) is ubiquitously
expressed in all fetal and adult tissues and encodes for a
serine-threonine protein kinase [9, 10]. It is involved in
the regulation of cell proliferation and polarity acting as
a tumor suppressor and also playing a crucial role in the
regulationofadenosine-5-monophosphate-activated protein
kinase energy homeostasis cascade [11, 12]. LKB1 mutants
fail to activate glycogen synthase kinase (GSK) 3β,t h u s ,
preventing it from inhibiting the Wnt signaling pathway
[13].
The dual phosphatase and tumor suppressor protein
PTEN also interacts with the LKB1 protein. Several LKB1
point mutations associated with PJS disrupt the interaction
with PTEN, suggesting that the loss of this interaction might
contribute to PJS. Since PTEN is mutated in autosomal
inherited disorders with phenotypes similar to those of PJS
(Bannayan-Riley-Ruvalcabasyndrome andCowdendisease),
there appears to be a functional link between the proteins
involved in diﬀerent hamartomatous polyposis syndromes,
thus,emphasizing the centralrole playedbyLKB1asatumor
suppressor in the intestine [14].
What current data is showing and what we nowadays are
based on is that STK11/LKB1 mutations can be recognized
in 84% and up to almost 100% of cases, depending on
the patient selection criteria and the methods used for
mutation search [7, 15]. In contrast, past studies of more
than a decade ago reported ambiguous results such as 50%
of PJS patients having no detectable germline mutation,
families not linked to 19p13-3, and even a possible second
PJS locus at 19p13-4 [16–19]. Genetic heterogeneity can
thus be expected. A genotype-phenotype correlation has
not been ﬁrmly established in PJS, probably owing to the
small size of reported series. There are some initial data,
however, suggesting that the absence of an LKB1 mutation
carries a higher risk of cancer development,especially biliary
carcinoma [20]. One study proposed that a mutation in
exon 3 of the LKB1 gene carries a higher cancer risk than
other LKB1 mutations [21]. Whereas clinical interfamilial
variation might simply reﬂect diﬀerent germline mutations,
intrafamilial variation is also well documented. The variabil-
ity includes the cancer risk, so better understanding should
have a signiﬁcant impact in forming individualized cancer
surveillance/screening programs [22].
3.Conclusion
Patients with PJS have a high risk of developing cancer with
it being around 85% by the age of 70 [23–25]. A large
recent study including 419 PJS patients reported a risk for
gastrointestinal cancers of 57% by the age of 70. Colorectal
cancer was the most common gastrointestinal cancer with a
lifetime risk of 39%, whereas the cumulative lifetime risk for
pancreatic cancer was 11% [24].
The risk of small bowel, gastric, and biliary cancer is
also increased. Extraintestinal cancers include gynecologic
n e o p l a s i a( b r e a s t ,o v a r y ,a n de n d o m e t r i u m ) .T h er e p o r t e d
risk of developing breast cancer ranges from 31% to 50%
[26]. Cancer is uncommon before the age of 30. The risk of
cervicalcarcinomas isnotincreased, butfemalepatientswith
PJS are at increased risk for the development of an adenoma
malignum, which may show rapid disease progression and
early dissemination. Almost all female patients with PJS
develop an otherwise rare potentially malignant ovarian
tumor, the sex cord tumor with annular tubules (SCTAT)
[27]. Malignant transformation is observed in 20% of all
cases. Cancers of the thyroid gland, gallbladder, and lung
also seem to be associated with PJS. Sertoli cell tumors are
considered to be the equivalent of SCTAT in male patients
with PJS and causes gynecomastia. The risk of malignancy is
estimated to be 10–20% [26, 28].
The well-recognized risk for patients with PJS to develop
cancer has led to the orchestration of various screening
programs.St.Mark’sHospitalPJSsurveillanceprogramisthe
most widely applied and comprises of upper gastrointestinal
endoscopyand colonoscopyevery 3 years. Given the rarity of
pancreatic cancerinthis setting,norecommendations canbe
made onpancreaticscreening inthese patients.Nevertheless,
as shown in our case, clinicians have to be aware that the
endopancreaticportionofthebileductcanalso bea location
forPJS-associated cancer.Thus,thepossibilityofmalignancy
in any case of jaundice in this population should be taken
into account before attributing the rising bilirubin to polyp-
derived obstruction that is the most common but benign
c a u s eo fj a u n d i c ei nt h e s ep a t i e n t s .
The occurrence of cholangiocarcinoma of endo-pancre-
atic common bile duct in our young patient with PJS was
characterized by the strikingly poor prognosis due to the4 HPB Surgery
inoperability of this case despite the immediate treatment
from the time of presentation. Thus, further research is
needed in order to elucidate the risk factors of this patient
population to develop malignant transformations of their
lesions. Proper risk stratiﬁcation and closer followup in
selected groups will promote well-timed diagnosis and
proper intervention that may be life-saving.
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